Beyond our impending OSA results, the wider Biotech sector will probably get some wind in its sails once some of the oodles of merger and acquisition funds start getting spent. Once those deals start getting publicized, funds should start flooding back in. Naturally, IXHL would be a solid punt in such a frothy environment.
General discussion, page-11475
-
- There are more pages in this discussion • 8,409 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)